gam-covid-vac (rad26)
Vaccineexperimental
Clinical trial activity
5 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 10, 2021 (NCT04686773)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
immunity, active - SARS-CoV-2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04684446 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2021 | AstraZeneca, Government of Russia, R-Pharm, The Gamaleya National Center of Epidemiology & Microbiology |
| NCT05027672 | Phase 2 | Jul 30, 2021 | Government of Argentina |
| NCT04954092 | Phase 2/Phase 3 (Phase 3) | Jul 5, 2021 | Government of Russia, Moscow City Health Department, Moscow Healthcare Department |
| NCT04760730 | Phase 1/Phase 2 (Phase 2) | Mar 17, 2021 | AstraZeneca, R-Pharm |
| NCT04686773 | Phase 2 | Feb 10, 2021 | AstraZeneca, Government of Russia, R-Pharm, The Gamaleya National Center of Epidemiology & Microbiology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 0 | 1 | 2021 |
| Government of Russia | Government | 3 | 1 | 2 | 2021 |
| R-Pharm | For profit | 3 | 3 | 1 | 2021 |
| The Gamaleya National Center of Epidemiology & Microbiology | Academic/Hospital | 2 | 0 | 1 | 2021 |
| Government of Argentina | Government | 1 | 1 | 1 | 2021 |
| Moscow City Health Department | Government | 1 | 0 | 1 | 2021 |
| Moscow Healthcare Department | Academic/Hospital | 1 | 0 | 1 | 2021 |
7 organizations
Page 1 / 1